Posters

Outcomes of the Ahmed FP7 valve in a small single-surgeon series with one year follow-up

Poster Details

First Author: D.Agius MALTA

Co Author(s):    J. Vassallo   O. Ajewole   E. Asajile   F. Carbonaro           

Abstract Details

Purpose:

This is a retrospective analysis of the outcomes of a single-surgeon series of a mixed patient population undergoing Ahmed valve implantation with one year of follow-up in one institution. The primary outcome was a target post-operative IOP of <21mmHg at 6 and 12 months, and the secondary outcome was a >30% reduction in intraocular pressure (IOP). The reduction in medication burden was also assessed.

Setting:

Procedures were carried out in the main public hospital of Malta (Mater Dei Hospital). The technique was introduced in this institution in November 2014. Patients operated between November 2014 and December 2016 were included in this review.

Methods:

This was a retrospective review of patient's hospital notes. There were 29 eyes of 27 patients, with a mean age of 63.6 years. All patients underwent a standard Ahmed FP-7 valve implantation with intra-operative mitomycin C. The collected data included patient and disease characteristics, pressure reduction, medication burden, and complications. Our results were compared with major published studies.

Results:

The mean IOP was 32.7mmHg (SD ±9.4) pre-operatively, 17.4mmHg (SD ±5.5) at six months, and 17.9mmHg (SD ±6.1) at one year. The IOP change at six months and one year was -15.1mmHg (SD ±10.4) and -14.6mmHg (SD ±11.1). An IOP <21mmHg was achieved in85.7% at one year, and an IOP reduction of >30% was obtained in 71.4%. The mean pre-operative number of different IOP-lowering drug classes was 3.86±1.13, with 82.8% being on oral acetazolamide. Post-operatively, the number of drug classes was 1.38±1.27, and 13.8% were on oral acetazolamide (p=<0.0001).

Conclusions:

The Ahmed valve offers a satisfactory IOP-lowering capability in different glaucoma types. The outcomes in this cohort were comparable to major published results, despite having a heterogeneous group of patients and a wider variety of primary and secondary glaucoma.

Financial Disclosure:

None